Jeff Slezak to Disease Progression
This is a "connection" page, showing publications Jeff Slezak has written about Disease Progression.
Connection Strength
0.328
-
Follow-up of Abnormal Estimated GFR Results Within a Large Integrated Health Care Delivery System: A Mixed-Methods Study. Am J Kidney Dis. 2019 11; 74(5):589-600.
Score: 0.039
-
The effect of urologist experience on choosing active surveillance for prostate cancer. World J Urol. 2015 Nov; 33(11):1701-6.
Score: 0.029
-
Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study. BJU Int. 2015 Jan; 115(1):127-33.
Score: 0.028
-
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
Score: 0.018
-
Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
Score: 0.017
-
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
Score: 0.016
-
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
Score: 0.015
-
International registry for primary hyperoxaluria. Am J Nephrol. 2005 May-Jun; 25(3):290-6.
Score: 0.015
-
Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000. BJU Int. 2005 May; 95(7):951-5.
Score: 0.015
-
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
Score: 0.014
-
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
Score: 0.014
-
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
Score: 0.013
-
Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol. 2002 Sep; 168(3):1204-11.
Score: 0.012
-
Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 2002 Aug; 34(4):363-71.
Score: 0.012
-
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 2002 Jan; 15(1):35-44.
Score: 0.012
-
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
Score: 0.011
-
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
Score: 0.010
-
Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc. 1999 Dec; 74(12):1214-20.
Score: 0.010
-
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999 Sep 15; 91(18):1574-80.
Score: 0.010
-
Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer. 1999 Aug 15; 86(4):657-63.
Score: 0.010
-
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
Score: 0.010